US · BNR · MEDICAL - DIAGNOSTICS & RESEARCH
Burning Rock Biotech Limited (BNR) intrinsic value and stock valuation
$13.24as of 2026-11-21 · Mkt cap 9.39M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Burning Rock Biotech Limited DCF and intrinsic value
InvestorsCraft values BNR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BNR’s statements →
Burning Rock Biotech Limited Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $539.6M | $515.8M | $537.4M | $563.2M | $507.9M |
| Operating income | -$-54.84M | -$-357.56M | -$-669.32M | -$-980.41M | -$-797.06M |
| Net income | -$-55.35M | -$-346.63M | -$-653.69M | -$-971.23M | -$-796.7M |
| EPSd | -$-51.25M | -$-33.69M | -$-63.84M | -$-93.48M | -$-76.46M |
| Operating cash flow | -$-28.44M | -$-92.26M | -$-255.78M | -$-456.81M | -$-477.89M |
| Capital expenditure | -$-5.25M | -$-5.98M | -$-9.38M | -$-62.03M | -$-213.45M |
| Free cash flow | -$-33.69M | -$-98.24M | -$-265.17M | -$-518.84M | -$-691.33M |
| Total assets | $820.9M | $885.3M | $1.04B | $1.59B | $2.28B |
| Total debt | $43.2M | $52.3M | $12.3M | $50.8M | $86.7M |
| Net debt | -$-438.25M | -$-467.53M | -$-602.77M | -$-854.66M | -$-1.34B |
| Total equity | $535.6M | $580.8M | $768.4M | $1.16B | $1.85B |
| Cash and short-term investments | $481.4M | $519.9M | $615.1M | $905.5M | $1.5B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $539.6M | $515.8M | $537.4M | $563.2M | $507.9M |
| Cost of revenue | $136.7M | $153.4M | $174.2M | $183.2M | $143.7M |
| Gross profit | $402.9M | $362.4M | $363.2M | $380M | $364.2M |
| Research and development expenses | $166.5M | $232.3M | $347M | $421.9M | $367.9M |
| Selling, general and administrative expenses | $291.3M | $452.5M | $685.5M | $938.6M | $793.4M |
| Other expenses | $0.00 | $35.1M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $457.8M | $720M | $1.03B | $1.36B | $1.16B |
| Cost and expenses | $594.4M | $873.4M | $1.21B | $1.54B | $1.3B |
| Interest income | $8.05M | $12.2M | $18M | $9.46M | $3.46M |
| Interest expense | $30K | $0.00 | $0.00 | $0.00 | $1.54M |
| Depreciation and amortization | $21.8M | $52.2M | $133.4M | $124.1M | $47.8M |
| Ebitda | -$-32M | -$-270.23M | -$-517.9M | -$-845.15M | -$-746.5M |
| Operating income | -$-54.84M | -$-357.56M | -$-669.32M | -$-980.41M | -$-797.06M |
| Total other income/expenses, net | $1.05M | $16.8M | $18M | $11.2M | $1.27M |
| Income before tax | -$-53.79M | -$-340.74M | -$-651.3M | -$-969.25M | -$-795.8M |
| Income tax expense | $1.56M | $5.88M | $2.39M | $1.99M | $900K |
| Net income | -$-55.35M | -$-346.63M | -$-653.69M | -$-971.23M | -$-796.7M |
| Weighted average shares outstanding | $1.08M | $10.3M | $10.2M | $10.4M | $10.4M |
| Weighted average diluted shares outstanding | $1.08M | $10.3M | $10.2M | $10.4M | $10.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $481.4M | $519.9M | $615.1M | $905.5M | $1.5B |
| Net receivables | $182M | $173.5M | $149.6M | $170.2M | $161.4M |
| Inventory | $57M | $53.8M | $69M | $130.3M | $123.2M |
| Total current assets | $739.1M | $776.6M | $884.1M | $1.26B | $1.82B |
| Property, plant and equipment, net | $73.9M | $100.3M | $144.2M | $300M | $406.4M |
| Goodwill and intangible assets | $280K | $420K | $960K | $1.99M | $5.15M |
| Long-term investments | $0.00 | $0.00 | $340K | $690K | $910K |
| Total non-current assets | $81.8M | $108.7M | $155.9M | $328.7M | $457.6M |
| Total assets | $820.9M | $885.3M | $1.04B | $1.59B | $2.28B |
| Accounts payable | $40.8M | $33.8M | $18.1M | $51M | $63.1M |
| Short-term debt | $17M | $24.6M | $8.63M | $37.2M | $37.4M |
| Deferred revenue | $107.9M | $118.5M | $131.7M | $149.4M | $143.8M |
| Total current liabilities | $247.1M | $266.3M | $263.4M | $411.5M | $372.2M |
| Long-term debt | $26.2M | $27.8M | $3.69M | $13.6M | $49.3M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $38.2M | $38.2M | $8.23M | $17.7M | $61.1M |
| Capital lease obligations | $41.2M | $52.3M | $12.3M | $50.8M | $84.3M |
| Total liabilities | $285.3M | $304.5M | $271.6M | $429.1M | $433.3M |
| Common stock | $140K | $140K | $140K | $140K | $140K |
| Retained earnings | -$-4.26B | -$-4.2B | -$-3.85B | -$-3.2B | -$-2.23B |
| Accumulated other comprehensive income (loss) | -$-162.24M | -$-158.05M | -$-161.53M | -$-165.72M | -$-207.07M |
| Total equity | $535.6M | $580.8M | $768.4M | $1.16B | $1.85B |
| Total investments | $0.00 | $0.00 | $340K | $690K | $64.7M |
| Total debt | $43.2M | $52.3M | $12.3M | $50.8M | $86.7M |
| Net debt | -$-438.25M | -$-467.53M | -$-602.77M | -$-854.66M | -$-1.34B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-55.35M | -$-346.63M | -$-653.69M | -$-971.23M | -$-796.7M |
| Depreciation and amortization | $21.8M | $52.2M | $133.4M | $124.1M | $47.8M |
| Stock-based compensation | $13.9M | $155.6M | $260.7M | $326.8M | $282.4M |
| Change in working capital | -$-59.39M | -$-36.53M | -$-52.16M | -$-11.16M | -$-62.4M |
| Accounts receivable | -$-33.23M | -$-26.8M | -$-12.39M | -$-42.16M | -$-18.93M |
| Inventory | $2.5M | $2.51M | $57.3M | -$-21.65M | -$-67M |
| Accounts payable | $7.18M | $18.9M | -$-31.12M | $16.6M | -$-5.1M |
| Net cash provided by operating activities | -$-28.44M | -$-92.26M | -$-255.78M | -$-456.81M | -$-477.89M |
| Investments in property, plant and equipment | -$-5.25M | -$-5.42M | -$-8.1M | -$-62.03M | -$-213.45M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $2.53M |
| Net cash used for investing activities | -$-4.39M | -$-4.41M | -$-9.3M | -$-7.46M | $81.7M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | -$-70K | -$-6.98M | -$-71.83M | -$-4.27M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $1.9M | -$-70K | -$-48.83M | -$-86.24M | -$-52.9M |
| Net change in cash | -$-41.07M | -$-93.05M | -$-310.05M | -$-513.84M | -$-486.09M |
| Cash at end of period | $481.1M | $522.2M | $615.2M | $925.3M | $1.44B |
| Operating cash flow | -$-28.44M | -$-92.26M | -$-255.78M | -$-456.81M | -$-477.89M |
| Capital expenditure | -$-5.25M | -$-5.98M | -$-9.38M | -$-62.03M | -$-213.45M |
| Free cash flow | -$-33.69M | -$-98.24M | -$-265.17M | -$-518.84M | -$-691.33M |
Line items
Line items
Line items
About Burning Rock Biotech Limited
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
- CEO
- Yusheng Han
- Employees
- 667
- Beta
- 1.33
Explore
Frequently asked questions
What is the intrinsic value of Burning Rock Biotech Limited (BNR)?
InvestorsCraft does not currently publish an intrinsic value for BNR. How the IC value is calculated.
Is BNR undervalued?
InvestorsCraft does not publish an undervaluation signal for BNR at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.